Volume 14, Issue 1 (2011)                   mjms 2011, 14(1): 59-69 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farshdousti Hagh M, Noruzinia M, Mortazavi Y, Soleimani M, Kaviani S, Mahmoodinia Maymand M. Epigenetic changes of RUNX2 and DLX5 genes in osteoblastic differentiation induced by zoledronic acid in mesenchymal stem cells. mjms 2011; 14 (1) :59-69
URL: http://mjms.modares.ac.ir/article-30-7995-en.html
1- Department of Hematology, Faculty of Medical Sciences,Tarbiat Modares University, Tehran, Iran
2- Assistant Professor, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3- Associated Professor, Department of Pathology, Faculty of Medicine, Zanjan University of Medical Sciences
4- Sarem Cell Research Center (SCRC), Tehran, Iran
Abstract:   (6147 Views)
Objective: Zoledronic acid as a main treatment for osteoporosis has an important role in differentiation of mesenchymal stem cells. However, mechanism of osteoblastic differentiation induction by zoledronic acid is not well understood until now. In this research we evaluate zoledronic acid effect on methylation status of RUNX2 and DLX5 promoters. Materials and Methods: After isolation and expansion of hMSCs from BM, they were pulse treated with 5μM ZA for 3h, and incubated in osteogenic differentiation medium for 3 weeks. DNA was extracted after first, second and third weeks of culture and also from undifferentiated MSCs. After SBS treatment, gene specific methylation analysis for RUNX2 and DLX5 were carried out by MSP using methylated and unmethylated primers. Results: In the genes RUNX2 and DLX5, M and U primers of MSP amplified promoter regions of undifferentiated and osteoblastic differentiated MSCs. Therefore, methylation status in RUNX2 and DLX5 promoters present incomplete methylation. Conclusion: Methyltion patterns of RUNX2 and DLX5 don’t change during zoledronic acid osteoblastic differentiation of MSCs. Our findings show that zoledronic acid does not induce osteoblastic differentiation via epigenetic mechanisms. Therefore, zoledronic acid can induce osteoblastic differentiation in a manner independent from DNA epigenetic changes.
Full-Text [PDF 1173 kb]   (4376 Downloads)    
Article Type: Original Manuscipt | Subject: Medical Genetics
Received: 2011/01/21 | Accepted: 2011/03/1

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.